

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-35. (cancelled)

Claim 36. (new) An antiallergic pharmaceutical composition, comprising: (i) an antihistamine compound, (ii) an inhibitor of histamine synthesis and, optionally, (iii) an allergen or an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said allergen, and said antihistamine compound, inhibitor, and optional allergen or isolated nucleic acid molecule being combined in said composition with a pharmaceutically acceptable carrier.

Claim 37. (new) The antiallergic pharmaceutical composition as claimed in claim 36, further comprising more than one antihistamine compound and more than one inhibitor of histamine synthesis.

Claim 38. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said antihistamine compound is chosen from the group consisting of brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxyzine, ketotifen, loratadine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochloride and doxylamine.

Claim 39. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said inhibitor of histamine synthesis is a histidine decarboxylase inhibitor.

Claim 40. (new) The antiallergic pharmaceutical composition as claimed in claim 39, wherein the histidine decarboxylase-inhibitor is tritoqualine.

Claim 41. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said antihistamine compound is present in an amount between 1 and 2000 mg.

Claim 42. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said antihistamine compound is present in an amount between 5 and 200 mg.

Claim 43. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said inhibitor of histamine synthesis is present in an amount between 1 and 2000 mg.

Claim 44. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said composition has from 5 to 200 mg of antihistamine and from 10 to 300 mg of a histidine decarboxylase inhibitor.

Claim 45. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said allergen is chosen from the major antigens or a mixture of major antigens of acarids, capable of inducing an immune reaction.

Claim 46. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said allergen is a major antigen of *D. Pteronyssinus* and/or *D. Farinae*.

Claim 47. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein the allergen is a cystine protease.

Claim 48. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein the allergen is at least one peptide epitope of a cystine protease.

Claim 49. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein the allergen is at least one peptide epitope of a cystine protease of sequence SEQ ID NO : 2.

Claim 50. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein the allergen is a peptide or a mixture of peptides chosen from the group consisting of the peptides of sequences SEQ ID NO : 3, SEQ ID NO : 4, and SEQ ID NO : 5.

Claim 51. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said allergen is natural and is obtained by extraction of the acarids *D. Pteronyssinus* and/or *D. Farinae*.

Claim 52. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said allergen is present in an amount of 1 to 1500 µg.

Claim 53. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said allergen is present in an amount of 10 to 150 µg.

Claim 54. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said isolated nucleic acid molecule comprises at least one polynucleotide sequence encoding said allergen is an adenoviral vector.

Claim 55. (new) The antiallergic pharmaceutical composition as claimed in claim 54, wherein said at least one polynucleotide sequence encoding said allergen comprises a sequence SEQ ID NO : 1.

Claim 56. (new) The antiallergic pharmaceutical composition as claimed in claim 54, wherein said at least one polynucleotide sequence encoding said allergen comprises a nucleotide sequence corresponding to the sequence SEQ ID NO : 6.

Claim 57. (new) The antiallergic pharmaceutical composition as claimed in claim 54, wherein said at least one polynucleotide sequence encoding said allergen is included in an isolated nucleic acid molecule comprising a nucleotide sequence corresponding to the sequence SEQ ID NO : 7.

Claim 58. (new) The antiallergic pharmaceutical composition as claimed in claim 54, wherein said composition is releasable in the form of a transcutaneous patch in order to allow better access of the allergen used, and/or of the at least one polynucleotide sequence encoding said allergen, to antigen-presenting cells.

Claim 59. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said composition is releasable in mucosal form, in the form of an eye lotion, in the form of a nasal spray, or in bronchial form.

Claim 60. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said composition is releasable in a pharmaceutical form for programmed disintegration mucosally or sublingually and secondarily *per os*.

Claim 61. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said composition is used to prepare a medicinal product intended for the treatment or for the prevention of the allergic hypersensitivity reaction.

Claim 62. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said composition is used to prepare a medicinal product intended for the treatment or for the prevention of allergic asthma, of allergic rhinitis, and of atopic and allergic eczema.

Claim 63. (new) The antiallergic pharmaceutical composition as claimed in claim 36, wherein said composition is used to prepare a medicinal product intended for the treatment or for the prevention of allergic manifestations in children, in infants and in adults.

Claim 64. (new) A use of a first allergen or of an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said first allergen, for preparing a pharmaceutical composition that is useful for treating or preventing an allergy caused by a second allergen different from the first allergen.

Claim 65. (new) The use as claimed in claim 64, wherein said first allergen is a cystine protease of an acarid.

Claim 66. (new) The use as claimed in claim 64, wherein said first allergen is a cystine protease of an acarid, and said second allergen is not a cystine protease of said acarid.

Claim 67. (new) The use as claimed in claim 64, wherein said first allergen is a cystine protease of a mite.

Claim 68. (new) The use as claimed in claim 64, wherein said first allergen is at least one peptide epitope of a cystine protease.

Claim 69. (new) The use as claimed in claim 68, wherein said first allergen is at least one peptide epitope of a cystine protease having the sequence SEQ ID NO:2.

Claim 70. (new) The use as claimed in claim 68, wherein said first allergen is a peptide or a mixture of peptides which are chosen from the group consisting of the peptides having the sequence SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.

Claim 71. (new) The use as claimed in claim 67, wherein said first allergen is natural and is obtained by extraction of *D. Pteronyssinus* and/or *D. Ferinae* from mites.

Claim 72. (new) The use as claimed in claim 67, wherein said second allergen is not a cystine protease of said mite.

Claim 73. (new) A method for making a pharmaceutical composition that is useful for treating an allergy caused by a first allergen comprising the steps of:

providing a second allergen different from said first allergen or an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said second allergen; and

preparing said pharmaceutical composition from said second allergen or said isolated nucleic acid molecule.